Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Stemedica Cell Technologies, Inc.
Sponsor:
Collaborators:
University of California, San Diego
Mercy Gilbert Medical Center at AZ
Chandler Regional Medical Center at Chandler AZ
Information provided by (Responsible Party):
Stemedica Cell Technologies, Inc.
ClinicalTrials.gov Identifier:
NCT01297413
First received: February 10, 2011
Last updated: April 7, 2014
Last verified: April 2014

February 10, 2011
April 7, 2014
February 2011
May 2015   (final data collection date for primary outcome measure)
The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period. [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period as determined by the incidence and severity of adverse events, clinically-significant changes on clinical laboratory tests, vital signs, physical and neurologic examinations.
Same as current
Complete list of historical versions of study NCT01297413 on ClinicalTrials.gov Archive Site
  • National Institutes of Health Stroke Scale Score. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    The change from the baseline in National Institutes of Health Stroke Scale score will be calculated at 1, 3, 6, 9, 12 months post-treatment, as available:
  • Mini Mental Status Exam score. [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
    The change from the baseline in Mini Mental Status Exam score will be calculated at 1, 3, 6, 9, 12 months post-treatment, as available.
  • Barthel Index Score. [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
    The change from the baseline in Barthel Index score at 1, 3, 6, 9, 12 months post-treatment, as available.
  • The Geriatric Depression Scale Score. [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
    The change from baseline in the Geriatric Depression Scale score at 1, 3, 6, 9, 12 months post-treatment, as available.
  • National Institutes of Health Stroke Scale. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    The change from the baseline in National Institutes of Health Stroke Scale score will be calculated at 1, 3, 6, 9, 12 months post-treatment, as available:
  • Mini Mental Status Exam score. [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
    The change from the baseline in Mini Mental Status Exam score will be calculated at 1, 3, 6, 9, 12 months post-treatment, as available.
  • Barthel Index. [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
    The change from the baseline in Barthel Index score at 1, 3, 6, 9, 12 months post-treatment, as available.
  • The Geriatric Depression Scale [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
    The change from baseline in the Geriatric Depression Scale score at 1, 3, 6, 9, 12 months post-treatment, as available.
Not Provided
Not Provided
 
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke
A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke

The purpose of this study is to assess the safety and tolerability of allogeneic adult mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke.

Stroke remains a major global healthcare problem. Recent data compiled by the American Heart Association (AHA) for 2008 show that the annual incidence of new or recurrent stroke in the United States is about 780,000, with approximately 600,000 of these strokes being first attacks. Among adults age 20 and older, the estimated prevalence of stroke in 2005 was 5.8 million in the United States, resulting in >150,000 deaths annually, with 4.8 million stroke survivors alive today. Stroke ranks as the country's third leading cause of death, behind only cancer and heart disease. The only approved treatments of acute ischemic stroke involve restoring blood flow to the affected region by using thrombolytics or mechanical devices that physically remove clots. However, the use of thrombolytics is limited due to the therapeutic window of < 3-6 hours post onset of stroke symptoms such that only a small fraction of stroke patients receive this therapy. Following the completion of a stroke, there is little therapy to offer patients to promote recovery other than physical, occupational, and speech therapy.

Allogeneic mesenchymal stem cells have been used in a number of clinical trials for different indications demonstrated the safety of allogeneic mesenchymal stem cell treatment. In addition to their ability to differentiate into multiple different cell types that would be contributory to the recovery and repair of the brain by replacing destroyed cells, mesenchymal stem cells also secrete angiogenins, cytokines and trophic factors that can support and stimulate multiple other cell types. The cascade of cellular events following the release of these cytokines and trophic factors would also potentially lead to beneficial effects by restoring blood supply, by rescuing cells at risk, and by stimulating the remaining cell populations to repair and propagate new cells and synaptic connections.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Ischemic Stroke
Biological: Allogeneic adult mesenchymal bone marrow stem cells
Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells
Experimental: Stem cells
All subjects will receive allogeneic adult mesenchymal bone marrow stem cells
Intervention: Biological: Allogeneic adult mesenchymal bone marrow stem cells
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
35
May 2016
May 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of ischemic stroke for longer than 6 months
  • Brain CT/MRI scan at initial diagnosis and at enrollment consistent with ischemic stroke
  • No substantial improvement in neurologic or functional deficits for the 2 months prior to enrollment
  • NIHSS score between 6-20
  • Life expectancy greater than 12 months
  • Prior to treatment patient received standard medical care for the secondary prevention of ischemic stroke
  • Adequate organ function as defined by the following criteria:

Exclusion Criteria:

  • History of uncontrolled seizure disorder
  • History of cancer within the past 5 years.
  • History of cerebral neoplasm
  • Positive for hepatitis B, C or HIV
  • Myocardial infarction withing six months of study entry
  • Findings on baseline CT suggestive of subarachnoid or intracerebral hemorrhage within past 12 months.
  • Allergies to Bovine or Porcine products
Both
18 Years and older
No
Contact: Sarah E Holland, RN, MSN, CCRC 858-966-8153
Contact: Ann Campbell, RN, BSN, CCRC 602-214-0886
United States
 
NCT01297413
STEM 101-M
Yes
Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc.
  • University of California, San Diego
  • Mercy Gilbert Medical Center at AZ
  • Chandler Regional Medical Center at Chandler AZ
Study Director: Lev Verkh, PhD Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc.
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP